{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T19:39:44Z","timestamp":1771011584560,"version":"3.50.1"},"reference-count":20,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2017,10,16]],"date-time":"2017-10-16T00:00:00Z","timestamp":1508112000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"Millennium Pharmaceuticals, Inc."}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2017,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>Brentuximab vedotin (BV) is an anti\u2010CD30 antibody\u2010drug conjugate licensed for the treatment of relapsed\/refractory Hodgkin lymphoma (rrHL) following autologous stem cell transplant (ASCT) or at least two prior therapies when ASCT or multiagent chemotherapy is not an option. The objective of this study was to describe real\u2010world outcomes with BV in patients with rrHL considered ASCT ineligible or who refuse ASCT.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This was a retrospective medical chart review study that enrolled patients \u226518\u00a0years old who were initially diagnosed with HL between January 1, 2008 and June 30, 2014, considered ASCT ineligible, and treated in routine care with BV for progressive disease after multidrug chemotherapy regimens. Clinical outcomes included best response to treatment, progression\u2010free survival (PFS), overall survival (OS), and adverse events.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 136 patients were included, with a median age of 70\u00a0years at initial HL diagnosis. The most common reasons for ASCT ineligibility were\u00a0comorbidities (74%) and age (57%). Overall response rate was 74%, and PFS and OS were 15.1 and 17.8\u00a0months, respectively. Peripheral neuropathy was observed in 9.6% of patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The results of this study provide real\u2010world evidence on the feasibility and effectiveness of BV in elderly or frail ASCT\u2010ineligible patients with rrHL in a real\u2010world setting.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ejh.12973","type":"journal-article","created":{"date-parts":[[2017,9,26]],"date-time":"2017-09-26T14:06:51Z","timestamp":1506434811000},"page":"553-558","source":"Crossref","is-referenced-by-count":18,"title":["Brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma who are Ineligible for autologous stem cell transplant: A Germany and United Kingdom retrospective study"],"prefix":"10.1111","volume":"99","author":[{"given":"Paul J.","family":"Br\u00f6ckelmann","sequence":"first","affiliation":[{"name":"Department I of Internal Medicine and German Hodgkin Study Group (GHSG) University Hospital of Cologne  Cologne Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erin A.","family":"Zagadailov","sequence":"additional","affiliation":[{"name":"Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited  Cambridge MA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4606-2971","authenticated-orcid":false,"given":"Shelby L.","family":"Corman","sequence":"additional","affiliation":[{"name":"Pharmerit International  Bethesda MD USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Viktor","family":"Chirikov","sequence":"additional","affiliation":[{"name":"Pharmerit International  Bethesda MD USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Courtney","family":"Johnson","sequence":"additional","affiliation":[{"name":"Pharmerit International  Bethesda MD USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cynthia","family":"Macahilig","sequence":"additional","affiliation":[{"name":"Medical Data Analytics  Parsippany NJ USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian","family":"Seal","sequence":"additional","affiliation":[{"name":"AstraZeneca  Gaithersburg MD USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehul R.","family":"Dalal","sequence":"additional","affiliation":[{"name":"Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited  Cambridge MA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tim","family":"Illidge","sequence":"additional","affiliation":[{"name":"Institute of Cancer Sciences Christie Hospital University of Manchester  Manchester UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2017,10,16]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61469-0"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.5807"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1408648"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)61940-5"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu181"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(93)92411-L"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)08938-9"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2012-0133"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-01-0039"},{"key":"e_1_2_7_11_1","first-page":"3736","article-title":"The anti\u2010CD30 monoclonal antibody SGN\u201030 promotes growth arrest and DNA fragmentation in vitro and affects antitumor activity in models of Hodgkin's disease","volume":"62","author":"Wahl AF","year":"2002","journal-title":"Cancer Res"},{"key":"e_1_2_7_12_1","first-page":"2697","article-title":"ALK+ lymphoma: clinico\u2010pathological findings and outcome","volume":"93","author":"Falini B","year":"1999","journal-title":"Blood"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.12.3681"},{"key":"e_1_2_7_14_1","unstructured":"WalewskiJ HellmanA SiritanaratkulN et\u00a0al.Single\u2010arm study of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma who are ineligible for stem cell transplantation or multi\u2010agent chemotherapy. 10th International Symposium on Hodgkin Lymphoma (ISHL); October 22\u201025 2016; Cologne Germany."},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2013.775434"},{"key":"e_1_2_7_16_1","first-page":"2","article-title":"Brentuximab vedotin (BV) an effective treatment for transplant ineligible patients with relapsed\/refractory (R\/R) Hodgkin lymphoma (HL)","volume":"100","author":"Viviani S","year":"2015","journal-title":"Haematologica"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2166"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2016.04.019"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-02-699850"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.0410"},{"key":"e_1_2_7_21_1","first-page":"Cd007941","article-title":"Comparison of first\u2010line chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for people with early unfavourable or advanced stage Hodgkin lymphoma","volume":"5","author":"Skoetz N","year":"2017","journal-title":"Cochrane Database Syst Rev"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fejh.12973","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.12973","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,7]],"date-time":"2023-10-07T17:13:49Z","timestamp":1696698829000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ejh.12973"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,16]]},"references-count":20,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["10.1111\/ejh.12973"],"URL":"https:\/\/doi.org\/10.1111\/ejh.12973","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,16]]}}}